Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania , Philadelphia, PA, USA.
Department of Pathology, Medical College of Wisconsin , Milwaukee, WI, USA.
Cancer Biol Ther. 2020 Jul 2;21(7):629-636. doi: 10.1080/15384047.2020.1750297. Epub 2020 May 7.
Within the microenvironment of solid tumors, stress associated with deficit of nutrients and oxygen as well as tumor-derived factors triggers the phosphorylation-dependent degradation of the IFNAR1 chain of type I interferon (IFN1) receptor and ensuing suppression of the IFN1 pathway. Here we sought to examine the importance of these events in malignant mammary cells. Expression of non-degradable IFNAR1 mutant in mouse mammary adenocarcinoma cells stimulated the IFN1 pathway yet did not affect growth of these cells in vitro or ability to form subcutaneous tumors in the syngeneic mice. Remarkably, these cells exhibited a notably accelerated growth when transplanted orthotopically into mammary glands. Importantly, in human patients with either ER+ or ER- breast cancers, high levels of IFNAR1 were associated with poor prognosis. We discuss the putative mechanisms underlying the pro-tumorigenic role of IFNAR1 in malignant breast cells.
在实体瘤的微环境中,与营养和氧气缺乏以及肿瘤衍生因子相关的应激会触发 I 型干扰素(IFN1)受体 IFNAR1 链的磷酸化依赖性降解,并随后抑制 IFN1 通路。在这里,我们试图研究这些事件在恶性乳腺细胞中的重要性。在鼠乳腺腺癌细胞中表达不可降解的 IFNAR1 突变体可刺激 IFN1 通路,但不会影响这些细胞在体外的生长或在同基因小鼠中形成皮下肿瘤的能力。值得注意的是,当这些细胞被原位移植到乳腺中时,它们的生长速度明显加快。重要的是,在患有 ER+或 ER-乳腺癌的人类患者中,IFNAR1 水平高与预后不良相关。我们讨论了 IFNAR1 在恶性乳腺细胞中发挥促肿瘤作用的潜在机制。